Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)

OBJECTIVES: Assess the efficacy and safety of tocilizumab in patients with systemic sclerosis (SSc) in a phase II study. METHODS: Patients with SSc were treated for 48 weeks in an open-label extension phase of the faSScinate study with weekly 162 mg subcutaneous tocilizumab. Exploratory end points i...

Descripción completa

Detalles Bibliográficos
Autores principales: Khanna, Dinesh, Denton, Christopher P, Lin, Celia J F, van Laar, Jacob M, Frech, Tracy M, Anderson, Marina E, Baron, Murray, Chung, Lorinda, Fierlbeck, Gerhard, Lakshminarayanan, Santhanam, Allanore, Yannick, Pope, Janet E, Riemekasten, Gabriela, Steen, Virginia, Müller-Ladner, Ulf, Spotswood, Helen, Burke, Laura, Siegel, Jeffrey, Jahreis, Angelika, Furst, Daniel E
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2018
Materias:
Clinical and Epidemiological Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867414/
https://www.ncbi.nlm.nih.gov/pubmed/29066464
http://dx.doi.org/10.1136/annrheumdis-2017-211682

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5867414/
https://www.ncbi.nlm.nih.gov/pubmed/29066464
http://dx.doi.org/10.1136/annrheumdis-2017-211682

Ejemplares similares